Results from a Phase II, randomized, non-comparative study showed that 54% of patients with stage III/IV treatment-naive NSCLC receiving the combination CP-751,871 plus carboplatin and paclitaxel (n=97) experienced objective responses. The response rate was 41% in patients treated with carboplatin and paclitaxel alone (n=53).
In addition, 78% of a subset of patients with squamous cell carcinoma (n=9) and 57% of a subset of patients with adenocarcinoma (n=28) receiving 20mg/kg of CP-751,871 plus carboplatin and paclitaxel experienced objective responses.
Response rates were 46% and 25%, respectively, for squamous cell (n=12) and adenocarcinoma patients (n=20) receiving carboplatin and paclitaxel alone. No response advantage with CP-751,871 was seen in a subset of patients with undifferentiated tumors.
Patients who received CP-751,871 20mg/kg showed the greatest improvement in progression-free survival (PFS). PFS was defined as either the length of time before the cancer progressed or death.
Antonio Gualberto, director and global clinical leader (oncology), Pfizer global R&D, said: “These data provide greater insight into the potential relationship between tumor histology and response to CP-751,871 observed in the clinical studies. Furthermore, the results support the global Phase III clinical trial program for CP-751,871 in NSCLC.”